- American City Business Journals•15 minutes ago
A new biotech has launched in Waltham with a management team made up of former Biogen executives and $38 million in financing from Pfizer, former Genzyme CEO Henri Termeer and other prominent investors. Arrakis Therapeutics said it will focus on developing potential treatments for neurology, cancer and rare genetic disorders that target RNA, the all-important molecules that translate the instructions in DNA into proteins in the body. The $38 million Series A financing was led by California venture capital firm Canaan Partners.
- TheStreet.com•2 days ago
The GOP has lit a match on tax reform, but nobody seems to know the length or texture of the fuse.
- Reuters•2 days ago
Pfizer Inc said it received subpoenas from the U.S. Attorney's Office for the District of Massachusetts related to its support for organizations that provide financial help to Medicare patients. "Pfizer is among a number of companies that have received subpoenas regarding this matter," the New York-based company said in an emailed statement on Friday. Drugmakers including Valeant Pharmaceuticals International Inc and Regeneron Pharmaceuticals Inc have disclosed involvement in similar government investigations.
PFE : Summary for Pfizer, Inc. - Yahoo Finance
Pfizer Inc. (PFE)
NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
|Day's Range||33.99 - 34.35|
|52 Week Range||28.74 - 37.39|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||29.21|
|Dividend & Yield||1.28 (3.74%)|
|1y Target Est||N/A|